Use the hyperlinks, where available to access additional clinical trial information.
A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
Eligible patients will be assigned to one of two experimental arms of the trial (Arm A or Arm B). In Arm A, patients will receive up to 8, 21-day cycles of glofitamab in combination with gemcitabine and oxaliplatin, followed by up to 4 cycles of glofitamab monotherapy. In this Arm, a single dose of obinutuzumab will be administered 7 days prior to the first dose of glofitamab. In Arm B, patients will receive up to 8 cycles of mosunetuzumab in combination with gemcitabine and oxaliplatin, administered in 21-day cycles.